Gender differences in hemorheological parameters and in in vitro platelet aggregation in acetylsalicylic acid and clopidogrel treated vascular patients

Katalin Koltai, Judit Papp, Peter Kenyeres, G. Fehér, Antal Tibold, Tamas Alexy, Zsolt Marton, Gabor Kesmarky, K. Tóth

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Sex-specific response to antiplatelet medications have been reported in several previous studies. OBJECTIVE: We investigated a possible connection between gender differences in hemorheological parameters and in vitro platelet aggregation in vascular patients treated with widely used antiplatelet agents. METHODS: In vitro platelet aggregation was assessed in 2687 patients treated with 100 mg acetylsalicylic acid (ASA), 1047 patients treated with 75 mg clopidogrel and 311 patients on dual antiplatelet therapy (100 mg aspirin and 75 mg clopidogrel) according to the method of Born. In subgroups of patients fibrinogen concentration, whole blood and plasma viscosity, red blood cell aggregation and hematocrit were simultaneously measured. The subjects were divided into groups according to their gender. RESULTS: ADP induced platelet aggregation was significantly higher in women in the case of ASA treatment (p <0.001). No gender differences could be observed in platelet function in patients treated with clopidogrel or on dual antiplatelet therapy. Hematocrit and whole blood viscosity were significantly higher in men in all groups (p <0.001), while no significant gender differences were observed in red blood cell aggregation indices in either group. Fibrinogen concentration was significantly higher in women than in men among patients treated with 100 mg ASA ( p <0.05), but not in the other groups. CONCLUSIONS: Significantly higher fibrinogen concentration found in aspirin treated women than men may play a role in higher ADP induced platelet aggregation. Gender differences in response to monotherapy suggest that benefits from combination therapy may be greater in females. The clinical relevance of higher ADP induced platelet aggregation in women treated with ASA needs further investigation.

Original languageEnglish
Pages (from-to)197-206
Number of pages10
JournalBiorheology
Volume51
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

clopidogrel
Platelet Aggregation
Aspirin
Blood Vessels
Adenosine Diphosphate
Fibrinogen
Cell Aggregation
Blood Viscosity
Hematocrit
Erythrocytes
Platelet Aggregation Inhibitors
Therapeutics
In Vitro Techniques

Keywords

  • Aspirin
  • Erythrocyte aggregation
  • Fibrinogen
  • Optical aggregometry
  • Thienopyridines
  • Viscosity

ASJC Scopus subject areas

  • Physiology (medical)
  • Physiology
  • Medicine(all)

Cite this

Gender differences in hemorheological parameters and in in vitro platelet aggregation in acetylsalicylic acid and clopidogrel treated vascular patients. / Koltai, Katalin; Papp, Judit; Kenyeres, Peter; Fehér, G.; Tibold, Antal; Alexy, Tamas; Marton, Zsolt; Kesmarky, Gabor; Tóth, K.

In: Biorheology, Vol. 51, No. 2, 2014, p. 197-206.

Research output: Contribution to journalArticle

Koltai, Katalin ; Papp, Judit ; Kenyeres, Peter ; Fehér, G. ; Tibold, Antal ; Alexy, Tamas ; Marton, Zsolt ; Kesmarky, Gabor ; Tóth, K. / Gender differences in hemorheological parameters and in in vitro platelet aggregation in acetylsalicylic acid and clopidogrel treated vascular patients. In: Biorheology. 2014 ; Vol. 51, No. 2. pp. 197-206.
@article{31362c1eb24d44cfb24e2f858fd3915d,
title = "Gender differences in hemorheological parameters and in in vitro platelet aggregation in acetylsalicylic acid and clopidogrel treated vascular patients",
abstract = "BACKGROUND: Sex-specific response to antiplatelet medications have been reported in several previous studies. OBJECTIVE: We investigated a possible connection between gender differences in hemorheological parameters and in vitro platelet aggregation in vascular patients treated with widely used antiplatelet agents. METHODS: In vitro platelet aggregation was assessed in 2687 patients treated with 100 mg acetylsalicylic acid (ASA), 1047 patients treated with 75 mg clopidogrel and 311 patients on dual antiplatelet therapy (100 mg aspirin and 75 mg clopidogrel) according to the method of Born. In subgroups of patients fibrinogen concentration, whole blood and plasma viscosity, red blood cell aggregation and hematocrit were simultaneously measured. The subjects were divided into groups according to their gender. RESULTS: ADP induced platelet aggregation was significantly higher in women in the case of ASA treatment (p <0.001). No gender differences could be observed in platelet function in patients treated with clopidogrel or on dual antiplatelet therapy. Hematocrit and whole blood viscosity were significantly higher in men in all groups (p <0.001), while no significant gender differences were observed in red blood cell aggregation indices in either group. Fibrinogen concentration was significantly higher in women than in men among patients treated with 100 mg ASA ( p <0.05), but not in the other groups. CONCLUSIONS: Significantly higher fibrinogen concentration found in aspirin treated women than men may play a role in higher ADP induced platelet aggregation. Gender differences in response to monotherapy suggest that benefits from combination therapy may be greater in females. The clinical relevance of higher ADP induced platelet aggregation in women treated with ASA needs further investigation.",
keywords = "Aspirin, Erythrocyte aggregation, Fibrinogen, Optical aggregometry, Thienopyridines, Viscosity",
author = "Katalin Koltai and Judit Papp and Peter Kenyeres and G. Feh{\'e}r and Antal Tibold and Tamas Alexy and Zsolt Marton and Gabor Kesmarky and K. T{\'o}th",
year = "2014",
doi = "10.3233/BIR-140661",
language = "English",
volume = "51",
pages = "197--206",
journal = "Biorheology",
issn = "0006-355X",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Gender differences in hemorheological parameters and in in vitro platelet aggregation in acetylsalicylic acid and clopidogrel treated vascular patients

AU - Koltai, Katalin

AU - Papp, Judit

AU - Kenyeres, Peter

AU - Fehér, G.

AU - Tibold, Antal

AU - Alexy, Tamas

AU - Marton, Zsolt

AU - Kesmarky, Gabor

AU - Tóth, K.

PY - 2014

Y1 - 2014

N2 - BACKGROUND: Sex-specific response to antiplatelet medications have been reported in several previous studies. OBJECTIVE: We investigated a possible connection between gender differences in hemorheological parameters and in vitro platelet aggregation in vascular patients treated with widely used antiplatelet agents. METHODS: In vitro platelet aggregation was assessed in 2687 patients treated with 100 mg acetylsalicylic acid (ASA), 1047 patients treated with 75 mg clopidogrel and 311 patients on dual antiplatelet therapy (100 mg aspirin and 75 mg clopidogrel) according to the method of Born. In subgroups of patients fibrinogen concentration, whole blood and plasma viscosity, red blood cell aggregation and hematocrit were simultaneously measured. The subjects were divided into groups according to their gender. RESULTS: ADP induced platelet aggregation was significantly higher in women in the case of ASA treatment (p <0.001). No gender differences could be observed in platelet function in patients treated with clopidogrel or on dual antiplatelet therapy. Hematocrit and whole blood viscosity were significantly higher in men in all groups (p <0.001), while no significant gender differences were observed in red blood cell aggregation indices in either group. Fibrinogen concentration was significantly higher in women than in men among patients treated with 100 mg ASA ( p <0.05), but not in the other groups. CONCLUSIONS: Significantly higher fibrinogen concentration found in aspirin treated women than men may play a role in higher ADP induced platelet aggregation. Gender differences in response to monotherapy suggest that benefits from combination therapy may be greater in females. The clinical relevance of higher ADP induced platelet aggregation in women treated with ASA needs further investigation.

AB - BACKGROUND: Sex-specific response to antiplatelet medications have been reported in several previous studies. OBJECTIVE: We investigated a possible connection between gender differences in hemorheological parameters and in vitro platelet aggregation in vascular patients treated with widely used antiplatelet agents. METHODS: In vitro platelet aggregation was assessed in 2687 patients treated with 100 mg acetylsalicylic acid (ASA), 1047 patients treated with 75 mg clopidogrel and 311 patients on dual antiplatelet therapy (100 mg aspirin and 75 mg clopidogrel) according to the method of Born. In subgroups of patients fibrinogen concentration, whole blood and plasma viscosity, red blood cell aggregation and hematocrit were simultaneously measured. The subjects were divided into groups according to their gender. RESULTS: ADP induced platelet aggregation was significantly higher in women in the case of ASA treatment (p <0.001). No gender differences could be observed in platelet function in patients treated with clopidogrel or on dual antiplatelet therapy. Hematocrit and whole blood viscosity were significantly higher in men in all groups (p <0.001), while no significant gender differences were observed in red blood cell aggregation indices in either group. Fibrinogen concentration was significantly higher in women than in men among patients treated with 100 mg ASA ( p <0.05), but not in the other groups. CONCLUSIONS: Significantly higher fibrinogen concentration found in aspirin treated women than men may play a role in higher ADP induced platelet aggregation. Gender differences in response to monotherapy suggest that benefits from combination therapy may be greater in females. The clinical relevance of higher ADP induced platelet aggregation in women treated with ASA needs further investigation.

KW - Aspirin

KW - Erythrocyte aggregation

KW - Fibrinogen

KW - Optical aggregometry

KW - Thienopyridines

KW - Viscosity

UR - http://www.scopus.com/inward/record.url?scp=84925351739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925351739&partnerID=8YFLogxK

U2 - 10.3233/BIR-140661

DO - 10.3233/BIR-140661

M3 - Article

C2 - 24898335

AN - SCOPUS:84925351739

VL - 51

SP - 197

EP - 206

JO - Biorheology

JF - Biorheology

SN - 0006-355X

IS - 2

ER -